Kovesdy received consulting fees from Abbott, Akebia, Ardelyx, Astra Zeneca, Bayer, Boehringer Ingelheim, Cara Therapeutics, CSL Behring, CSL Vifor, GSK, Pharmacosmos, ProKidney, Renibus and Takeda
Physiol Rep 11(24):e15896
Even though under normal circumstances dietary inorganic sulfate contributes very little to our sulfate pool, the exogenous administration of small amounts of sulfate in selected forms of delivery may be useful, since contrary to what is still a common belief sulfate can be absorbed form the GI tract [41, 51]
Manufacturing capacity, regulatory requirements and market demand are important factors that may impact this timeline
What fascinates me most about BPC-157 is how it seems to work with the bodys existing repair mechanisms rather than overriding them